GigaGen to Present Data on Recombinant Hyperimmune Gammaglobulin at the 18th Biennial Meeting of the European Society for Immunodeficiencies


SOUTH SAN FRANCISCO, Calif., Oct. 26, 2018 /PRNewswire/ -- GigaGen Inc., a biopharmaceutical company developing novel antibody therapies, today announced a data presentation at the 18th Biennial Meeting of the European Society for Immunodeficiencies (ESID). Rena Mizrahi, Ph.D., director of protein engineering, will present on the company's proprietary recombinant hyperimmune gammaglobulin program. The conference takes place October 24-27, 2018, at the Centro de Congressos de Lisboa in Libson, Portugal.

Logo (PRNewsfoto/GigaGen Inc.)

"Our data being presented at ESID validates the therapeutic potential of our novel recombinant hyperimmune gammaglobulin, generated by our Surge platform, to deliver increased potency and antigen specificity relative to existing plasma-derived products," said David Johnson, Ph.D., chief executive officer. "We are now in the process of evaluating efficacy in additional studies and look forward to moving this program toward the clinic to help immune deficient patients fight harmful pathogens, including bacterial infections."

Details of GigaGen's ESID 2018 presentation are as follows:

Abstract Number: 288
Title: "Recombinant Hyperimmune Gammaglobulin for Recurrent Bacterial Infections in Primary Immune Deficiency"
Poster Date and Time: Friday, October 26, 2018 at 7:30 a.m. - Saturday, October 27 at 1:45 p.m. WEST

About GigaGen
GigaGen is a privately-held, preclinical biopharmaceutical company developing novel antibody therapies to treat diseases of immune dysregulation. GigaGen's deep understanding of immune dysregulation is enabled by industry-leading technology that quickly captures the genetic makeup of entire immune repertoires to analyze B cells at a rate of millions per hour, while simultaneously identifying their antigen and protein binders. GigaGen has a robust internal pipeline consisting of novel antibodies against immuno-oncology targets, in addition to the first recombinant intravenous immunoglobulin (IVIG) for patients with immune deficiency. For more information visit

Cision View original content to download multimedia:

SOURCE GigaGen Inc.


Back to news